Infinity Pharma: One cancer drug advances, one ends development

Thu, 05/19/2011 - 10:42am
Mass High Tech: The Journal of New England Technology

Infinity Pharmaceuticals Inc. (Nasdaq:INFI) is launching a Phase 2 trial of its potential treatment for non-small cell lung cancer, retaspimycin HCl in combination with the approved chemotherapy drug, Taxotere, marketed by French drug maker Sanofi (NYSE: SNY). The Cambridge-based biotechnology company also said it would halt development on a second potential cancer treatment, known at IPI-493, because it did not perform as well in trials as retaspimycin HCl.

The new trial follows positive results from a Phase 1-b trial for retaspimycin HCl and Taxotere, which showed the two drugs were well-tolerated when taken together and that it showed clinical activity in some of the sickest patients.



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.